Cargando…
Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564667/ https://www.ncbi.nlm.nih.gov/pubmed/37725166 http://dx.doi.org/10.1007/s00401-023-02631-8 |
| _version_ | 1785118528448233472 |
|---|---|
| author | VandeVrede, Lawren La Joie, Renaud Horiki, Sheena Mundada, Nidhi S. Koestler, Mary Hwang, Ji-Hye Ljubenkov, Peter A. Rojas, Julio C. Rabinovici, Gil D. Boxer, Adam L. Seeley, William W. |
| author_facet | VandeVrede, Lawren La Joie, Renaud Horiki, Sheena Mundada, Nidhi S. Koestler, Mary Hwang, Ji-Hye Ljubenkov, Peter A. Rojas, Julio C. Rabinovici, Gil D. Boxer, Adam L. Seeley, William W. |
| author_sort | VandeVrede, Lawren |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10564667 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105646672023-10-12 Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab VandeVrede, Lawren La Joie, Renaud Horiki, Sheena Mundada, Nidhi S. Koestler, Mary Hwang, Ji-Hye Ljubenkov, Peter A. Rojas, Julio C. Rabinovici, Gil D. Boxer, Adam L. Seeley, William W. Acta Neuropathol Correspondence Springer Berlin Heidelberg 2023-09-19 2023 /pmc/articles/PMC10564667/ /pubmed/37725166 http://dx.doi.org/10.1007/s00401-023-02631-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence VandeVrede, Lawren La Joie, Renaud Horiki, Sheena Mundada, Nidhi S. Koestler, Mary Hwang, Ji-Hye Ljubenkov, Peter A. Rojas, Julio C. Rabinovici, Gil D. Boxer, Adam L. Seeley, William W. Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab |
| title | Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab |
| title_full | Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab |
| title_fullStr | Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab |
| title_full_unstemmed | Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab |
| title_short | Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab |
| title_sort | co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564667/ https://www.ncbi.nlm.nih.gov/pubmed/37725166 http://dx.doi.org/10.1007/s00401-023-02631-8 |
| work_keys_str_mv | AT vandevredelawren copathologymayimpactoutcomesofamyloidtargetingtreatmentsclinicopathologicalresultsfromtwopatientstreatedwithaducanumab AT lajoierenaud copathologymayimpactoutcomesofamyloidtargetingtreatmentsclinicopathologicalresultsfromtwopatientstreatedwithaducanumab AT horikisheena copathologymayimpactoutcomesofamyloidtargetingtreatmentsclinicopathologicalresultsfromtwopatientstreatedwithaducanumab AT mundadanidhis copathologymayimpactoutcomesofamyloidtargetingtreatmentsclinicopathologicalresultsfromtwopatientstreatedwithaducanumab AT koestlermary copathologymayimpactoutcomesofamyloidtargetingtreatmentsclinicopathologicalresultsfromtwopatientstreatedwithaducanumab AT hwangjihye copathologymayimpactoutcomesofamyloidtargetingtreatmentsclinicopathologicalresultsfromtwopatientstreatedwithaducanumab AT ljubenkovpetera copathologymayimpactoutcomesofamyloidtargetingtreatmentsclinicopathologicalresultsfromtwopatientstreatedwithaducanumab AT rojasjulioc copathologymayimpactoutcomesofamyloidtargetingtreatmentsclinicopathologicalresultsfromtwopatientstreatedwithaducanumab AT rabinovicigild copathologymayimpactoutcomesofamyloidtargetingtreatmentsclinicopathologicalresultsfromtwopatientstreatedwithaducanumab AT boxeradaml copathologymayimpactoutcomesofamyloidtargetingtreatmentsclinicopathologicalresultsfromtwopatientstreatedwithaducanumab AT seeleywilliamw copathologymayimpactoutcomesofamyloidtargetingtreatmentsclinicopathologicalresultsfromtwopatientstreatedwithaducanumab |